Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BRF113929: An Open-Label, Two-Cohort, Multicentre Study of GSK2118436 as a Single Agent in Treatment Naïve and Previously Treated Subjects With BRAF Mutation-Positive Metastatic Melanoma to the Brain

NCT01266967 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01266967
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01266967 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BRF113929: An Open-Label, Two-Cohort, Multicentre Study of GSK2118436 as a Single Agent in Treatment Naïve and Previously Treated Subjects With BRAF Mutation-Positive Metastatic Melanoma to the Brain
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2011
Completion date
November 30, 2012
Enrollment
172 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma and brain metastases